Letter to the editor

European Urology

Volumn 58, Issue 3, 2010, Pages

  Spahn, Martin ^a,b   Kneitz, Burkhard ^a   Gontero, Paolo ^c   Van Poppel, Hein ^d   Joniau, Steven ^d  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b General Hospital Karlsruhe   (Germany)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; PROSTATE SPECIFIC ANTIGEN;

CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DISEASE SEVERITY; GENE EXPRESSION REGULATION; GLEASON SCORE; HUMAN; LETTER; MONOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY; TREATMENT OUTCOME; CANCER MORTALITY; CANCER RISK; FOLLOW UP; HIGH RISK PATIENT; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; TUMOR GROWTH;

EID: 77955513706     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.05.022     Document Type: Letter

References (12)

1. E.Z. Neulander, Z. Wejsman, Re: Martin Spahn, Steven Joniau, and Paolo Gontero Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients Eur Urol 58 2010 e36
2. E. Neulander, I. Skoneczna, W. Murphy, A. Douvdevani, I. Rivera, and Z. Wajsman Radical prostatectomy in patients with preoperative prostate specific antigen 15 ng/ml and higher NOWOTWORY J Oncol 52 2002 190 194
3. M. Spahn, S. Joniau, and P. Gontero Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients Eur Urol 58 2010 1 7
4. M. Spahn, C. Weiss, and P. Bader Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation Urol Int 84 2010 164 173
5. M.D. Shelley, S. Kumar, B. Coles, T. Wilt, J. Staffurth, and M.D. Mason Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials Cancer Treat Rev 35 2009 540 546
6. D.G. McLeod, P. Iversen, W.A. See, T. Morris, J. Armstrong, and M.P. Wirth Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer BJU Int 97 2006 247 254
7. P. Gontero, S. Kneitz, and B. Kneitz The role of adjuvant hormonal treatment after surgery for high-risk localised prostate cancer-results of a multi-institutional matched analysis Eur Urol Suppl 9 2010 225 Abstract 686
8. Heidenreich A, Bolla M, Joniau S, et al. Guidelines on prostate cancer. European Association of Urology Web site. http://www.uroweb.org/?id=218%26gid=3. Updated 2010.
9. I.M. Thompson, C.M. Tangen, and J. Paradelo Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 2009 956 962
10. A. Briganti, M. Spahn, and S. Joniau Predicting favourable pathological outcome in patients with clinical high risk prostate cancer. A novel nomogram based on a multi-institutional analysis Eur Urol Suppl 9 2010 317 318 Abstract 1013
11. G.A. Calin, and C.M. Croce MicroRNA signatures in human cancers Nat Rev Cancer 6 2006 857 866
12. Spahn M, Kneitz S, Scholz CJ, et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer. In press.